{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:18:23Z","timestamp":1768821503063,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T00:00:00Z","timestamp":1158969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2006,11,17]]},"DOI":"10.1007\/s10792-006-9006-9","type":"journal-article","created":{"date-parts":[[2006,10,7]],"date-time":"2006-10-07T20:22:34Z","timestamp":1160252554000},"page":"83-92","source":"Crossref","is-referenced-by-count":62,"title":["Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"26","author":[{"given":"Ahmed M.","family":"Abu El-Asrar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad B.","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Aldibhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Al-Arfaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,23]]},"reference":[{"key":"9006_CR1","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"9006_CR2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1517\/13543784.9.9.1993","volume":"9","author":"T Sakane","year":"2000","unstructured":"Sakane T, Takeno M (2000) New approaches to Beh\u00e7et\u2019s disease. Exp Opin Invest Drugs 9:1993\u20132005","journal-title":"Exp Opin Invest Drugs"},{"key":"9006_CR3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Beh\u00e7et\u2019s disease: an analysis of 880 patients. Am J Ophthalmol 138:373\u2013380","journal-title":"Am J Ophthalmol"},{"key":"9006_CR4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z","volume":"42","author":"MA Frassanito","year":"1999","unstructured":"Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Beh\u00e7et\u2019s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967\u20131974","journal-title":"Arthritis Rheum"},{"key":"9006_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ajo.2004.04.046","volume":"138","author":"AM Abu El-Asrar","year":"2004","unstructured":"Abu El-Asrar AM, Struyf S, Descamps FJ, Al-Obeidan SA, Proost P, Van Damme J et al. (2004) Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol 138:401\u2013411","journal-title":"Am J Ophthalmol"},{"key":"9006_CR6","first-page":"1544","volume":"20","author":"JL Mage","year":"1993","unstructured":"Mage JL, Dilsen N, Sanguedolce V, Gul A, Bangrand P, Roux H et al. (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544\u20131549","journal-title":"J Rheumatol"},{"key":"9006_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cyto.2003.09.003","volume":"24","author":"M Misumi","year":"2003","unstructured":"Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T et al. (2003) Cytokine production profile in patients with Beh\u00e7et\u2019s disease treated with infliximab. Cytokine 24:210\u2013218","journal-title":"Cytokine"},{"key":"9006_CR8","first-page":"128","volume":"24","author":"B Turan","year":"1997","unstructured":"Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM (1997) Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et\u2019s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 24:128\u2013132","journal-title":"J Rheumatol"},{"key":"9006_CR9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, Turkoz Y, Cekmen M (2002) Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediat Inflamm 11:87\u201393","journal-title":"Mediat Inflamm"},{"key":"9006_CR10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1076\/ocii.12.1.53.28062","volume":"12","author":"Y Bardak","year":"2004","unstructured":"Bardak Y, Aridogan BC (2004) The demonstration of serum interleukin 6\u20138, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Beh\u00e7et\u2019s disease with ocular involvement. Ocul Immunol Inflamm 12:53\u201358","journal-title":"Ocul Immunol Inflamm"},{"key":"9006_CR11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","volume":"33","author":"M Santos Lacomba","year":"2001","unstructured":"Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gomez Vidal MA, Collantes Estevez E, Ramirez Chamond R et al. (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251\u2013255","journal-title":"Ophthalmic Res"},{"key":"9006_CR12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1167\/iovs.03-0659","volume":"45","author":"K Greiner","year":"2004","unstructured":"Greiner K, Murphy CC, Willermain F, Duncan L, Plskova J, Hale G et al (2004) Anti-TNF ( therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophth Vis Sci 45:170\u2013176","journal-title":"Invest Ophth Vis Sci"},{"key":"9006_CR13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N (2004) Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et\u2019s disease. Ann Intern Med 140:404\u2013406","journal-title":"Ann Intern Med"},{"key":"9006_CR14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","volume":"110","author":"A Joseph","year":"2003","unstructured":"Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ (2003) Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110:1449\u20131453","journal-title":"Ophthalmology"},{"key":"9006_CR15","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al. (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease. Arthritis Rheum 52:2478\u20132484","journal-title":"Arthritis Rheum"},{"key":"9006_CR16","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Makamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M et al. (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis. J Rheumatol 31:1362\u20131368","journal-title":"J Rheumatol"},{"key":"9006_CR17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.61.suppl_2.ii51","volume":"61","author":"PP Sfikakis","year":"2002","unstructured":"Sfikakis PP (2002) Beh\u00e7et\u2019s disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 61:51\u201353","journal-title":"Ann Rheum Dis"},{"key":"9006_CR18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","volume":"89","author":"EW Lindstedt","year":"2005","unstructured":"Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM (2005) Anti-TNF-\u03b1 therapy for sight threatening uveitis. Br J Ophthalmol 89:533\u2013536","journal-title":"Br J Ophthalmol"},{"key":"9006_CR19","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","volume":"34","author":"N Lantbier","year":"2005","unstructured":"Lantbier N, Parc C, Scavennec R, Db\u00f4te R, Br\u00e9zin AP, Guillevin L (2005) Infliximab in the treatment of posterior uveitis in Beh\u00e7et\u2019s disease: long term follow-up in four patients. Press Med 34:916\u2013918","journal-title":"Press Med"},{"issue":"4 Suppl 34","key":"9006_CR20","first-page":"S14","volume":"22","author":"B Wechsler","year":"2004","unstructured":"Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I et al. (2004) Infliximab in refractory uveitis due to Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 22[Suppl 4]:S14\u2013S16","journal-title":"Clin Exp Rheumatol"},{"key":"9006_CR21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.eye.6701792","volume":"19","author":"JM Benitez-del-Castillo","year":"2005","unstructured":"Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Mendez-Fernandez R, Lopez-Abad C, Matilla M, Garcia-Sanchez J (2005) Long-term treatment of refractory posterior uveitis with anti-TNF alpha (infliximab). Eye 19:831\u2013833","journal-title":"Eye"},{"key":"9006_CR22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Werheim MS, Lauer AK, Kurz DE, Richard TD et al. (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903\u2013912","journal-title":"Arch Ophthalmol"},{"key":"9006_CR23","first-page":"5","volume-title":"Posterior uveitis: diagnosis and management","author":"JV Forrester","year":"1994","unstructured":"Forrester JV, Ben Ezra D, Nussenblatt RB, Tabbara KF, Timonen P (1994) Grading of intermediate, posterior uveitis. In: Tabbara KF, Nussenblatt RB (eds) Posterior uveitis: diagnosis and management. Butterworth-Heinemann, Boston, pp 5\u201318"},{"key":"9006_CR24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","volume":"138","author":"NN Markomichelakis","year":"2004","unstructured":"Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138:648\u2013650","journal-title":"Am J Ophthalmol"},{"key":"9006_CR25","first-page":"2557","volume":"30","author":"M Louis","year":"2003","unstructured":"Louis M, Rauch J, Armstrong M, Fitzcharles MA (2003) Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 30:2557\u20132562","journal-title":"J Rheumatol"},{"key":"9006_CR26","first-page":"756","volume":"22","author":"Y Allanore","year":"2004","unstructured":"Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A (2004) Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 22:756\u2013758","journal-title":"Clin Exp Rheumatol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-006-9006-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-006-9006-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-006-9006-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:24:08Z","timestamp":1559262248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-006-9006-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,23]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,11,17]]}},"alternative-id":["9006"],"URL":"https:\/\/doi.org\/10.1007\/s10792-006-9006-9","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,23]]}}}